Herbs (Global Traditional) · Ayurveda
Triphala (Terminalia chebula) (Terminalia chebula)
Strong Evidencebotanical
Hermetica Superfood Encyclopedia
Triphala is an Ayurvedic herbal formula combining three fruits, with Terminalia chebula as a key component containing chebulagic acid and gallotannins. It demonstrates antioxidant and anti-inflammatory effects through COX and 5-LOX enzyme inhibition.
Triphala is a traditional Ayurvedic formulation composed of dried fruits from three plants: Terminalia chebula (Haritaki), Terminalia bellirica, and Phyllanthus emblica (Amla), with T. chebula often being the dominant ingredient. The ripe fruits are harvested from South Asia, particularly India, then dried and powdered or decocted in water for extraction.
No human clinical trials, RCTs, or meta-analyses for Triphala or Terminalia chebula were found in the research dossier. Current evidence is limited to in vitro and animal studies demonstrating antioxidant, anti-inflammatory, and anticancer activities.
No clinically studied dosage ranges are available from human trials. Traditional preparations involve decocting dried fruits in a 1:20 ratio (120g T. chebula:80g T. bellirica:40g P. emblica in 2500mL water). Consult a healthcare provider before starting any new supplement.
Triphala (Terminalia chebula) is a complex herbal formulation with the following key components and approximate concentrations: **Primary Bioactive Compounds:** - Tannins (total): 30–45% dry weight, predominantly hydrolyzable tannins - Chebulagic acid: 1.5–4.0% dry weight (ellagitannin; key bioactive) - Chebulinic acid: 1.0–3.5% dry weight (ellagitannin) - Ellagic acid: 0.5–2.0% dry weight (polyphenol) - Gallic acid: 2.0–5.0% dry weight (phenolic acid) - Corilagin: 0.3–1.2% dry weight (gallotannin) - Terchebulin: trace–0.8% dry weight - Punicalagin: trace amounts **Phenolic Content:** - Total phenolics: 150–400 mg GAE/g dry extract (varies by preparation method) - Flavonoids: 10–30 mg QE/g dry extract - Anthocyanins: minor amounts (<1 mg/g) **Macronutrients (per 100g crude powder):** - Carbohydrates: 40–60g (primarily complex polysaccharides and fiber) - Dietary fiber: 15–25g - Proteins: 3–6g - Fats: 0.5–2g - Moisture: 8–12g **Micronutrients:** - Vitamin C (ascorbic acid): 5–15 mg/100g (lower than fresh fruit due to processing) - Iron: 2–4 mg/100g - Calcium: 150–300 mg/100g - Phosphorus: 80–150 mg/100g - Potassium: 200–400 mg/100g - Manganese: 1–3 mg/100g - Zinc: 0.5–1.5 mg/100g **Other Bioactives:** - Anthraquinones: trace amounts - Saponins: 0.5–1.5% - Terpenoids (including arjungenin): minor concentrations - Fixed oils (in seed): 30–45% of seed weight, rich in oleic and linoleic acids **Bioavailability Notes:** - Tannins (chebulagic acid, chebulinic acid) have relatively low oral bioavailability (~1–5%) due to large molecular weight and poor GI absorption; however, gut microbiota metabolize these into bioavailable urolithins and ellagic acid metabolites - Gallic acid exhibits significantly higher bioavailability (~70–90% absorbed in small intestine) compared to larger tannins - Ellagic acid undergoes rapid phase II metabolism; its gut-derived metabolites (urolithins A and B) are considered the primary systemically active forms - Aqueous extracts (decoctions) yield higher polyphenol concentration than ethanol extracts for some tannins - Bioavailability of minerals is moderate, potentially reduced by high tannin content through chelation - Co-administration with food may slow absorption but improve tolerability - Individual variation in gut microbiome composition significantly affects conversion of ellagitannins to active metabolites
Chebulagic acid in Terminalia chebula provides dual inhibition of cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) enzymes, reducing inflammatory mediator production. The phenolic compounds and gallotannins contribute antioxidant activity by scavenging free radicals and chelating metal ions. These bioactive compounds work synergistically to modulate inflammatory pathways and oxidative stress responses.
Current evidence for Triphala comes primarily from in vitro laboratory studies demonstrating antioxidant activity through phenolic and tannin content in aqueous extracts. Preliminary laboratory research shows anti-inflammatory effects via chebulagic acid's enzyme inhibition properties. Limited preliminary research suggests potential anticancer activity, though human clinical trials are lacking. The evidence base remains in early stages with most data from cell culture and animal studies rather than human clinical trials.
Triphala is generally well-tolerated but may cause gastrointestinal upset, diarrhea, or cramping in sensitive individuals, especially at higher doses. It may interact with diabetes medications due to potential blood sugar-lowering effects and could enhance the effects of anticoagulant drugs. Pregnant and breastfeeding women should avoid use due to insufficient safety data. People with bleeding disorders or scheduled for surgery should discontinue use at least two weeks prior due to potential bleeding risk.
